Table 2.
Baseline plasma concentrations of EPA, DPA, DHA, AA and their derived lipid mediators in non-responders versus responders in the combined active treatment arms (EPA 1 g/d, 2 g/d, and 4 g/d).
| Non-responders (n = 19) | Responders (n = 16) | P value* | |
|---|---|---|---|
| EPA | |||
| EPA, mol% | 0.42 (0.32) | 0.43 (0.36) | 0.85 |
| 5-HEPE, pg/mL | 50 (29) | 55 (53) | 0.31 |
| 11-HEPE, pg/mL | 43 (48) | 49 (38) | 0.70 |
| 12-HEPE, pg/mL | 806 (2094) | 588 (1838) | 0.60 |
| 15S-HEPE, pg/mL | 92 (62) | 79 (87) | 0.67 |
| 18-HEPE, pg/mL | 47 (29) | 47 (25) | 0.88 |
| DPA | |||
| DPA, mol% | 0.37 (0.17) | 0.34 (0.26) | 0.83 |
| RvD5 DPA, pg/mL | 15 (6) | 14 (3) | 0.73 |
| DHA | |||
| DHA, mol% | 7.42 (4.59) | 7.11 (3.40) | 0.42 |
| 4-HDHA, pg/mL | 60 (45) | 56 (39) | 0.57 |
| 7-HDHA, pg/mL | 18 (14) | 18 (17) | 0.93 |
| 13-HDHA, pg/mL | 145 (251) | 165 (248) | 0.60 |
| 14-HDHA, pg/mL | 1810 (4012) | 1580 (2254) | 0.55 |
| 17-HDHA, pg/mL | 30 (25) | 31 (26) | 0.82 |
| RvD1, pg/mL | 85 (103) | 120 (121) | 0.95 |
| AA | |||
| AA, mol% | 10.11 (3.68) | 10.52 (5.66) | 0.80 |
| 5-HETE, pg/mL | 355 (326) | 445 (515) | 0.40 |
| 11-HETE, pg/mL | 1603 (1956) | 1234 (2225) | 0.67 |
| 12-HETE, pg/mL | 9622 (13191) | 9502 (15867) | 0.99 |
| 15-HETE, pg/mL | 1182 (689) | 1306 (1268) | 0.53 |
| PGE2, pg/mL | 1139 (1536) | 965 (1904) | 0.80 |
| TXB2, pg/mL | 2634 (3220) | 1528 (4013) | 0.72 |
| LTB4, pg/mL | 31 (17) | 21 (29) | 0.29 |
Median (IQR); *P value, Wilcoxon rank-sum test.